Development of distant metastasis remains high in locally advanced rectal cancer patients treated with a trimodal approach. We intensified the neoadjuvant treatment regimen by adding oxaliplatin to the standard 5- fluorouracil. Five-year follow-up data were encouraging, with excellent disease control rates and long-term survival. An oxaliplatin-based combination in the neoadjuvant setting could be a valid treatment option. Purpose: To report the long-term follow-up data and determine the toxicity rate concerning patients with locally advanced rectal cancer (LARC) treated with an intensified neoadjuvant treatment regimen. Patients and Methods: Patients with histologically proven stage II to III adenocarcinoma of the rectum were included and treated with a trimodal approach. Intensified neoadjuvant treatment (chemoradiotherapy [CRT]) consisted of radiotherapy (total dose 50.4/54 Gy) and concomitant oxaliplatin (50 mg/m2 /week) and 5-fluorouracil (200 mg/m2 /5 daily continuous infusion). Surgery was planned 7 to 9 weeks after the end of CRT. Adjuvant chemotherapy was recommended in those patients with lymph node metastasis at diagnosis. Results: One hundred patients (median age, 64 years) were eligible. Overall, the 5-year overall survival and disease-free survival (DFS) were 76.4% and 74.5%, respectively. CRT was well tolerated, with only 17% grade 3/4 acute toxicity. Twenty-four patients (24%) had a pathologic complete response (pCR), and only 1 patient had perioperative metastasis. The 5-year DFS were 95.7% and 66.7% for pCR and no-pCR tumor histology, respectively (P ¼ .0275). Conclusion: Although oxaliplatin is not considered to be a standard treatment, the high 5-year rate of overall survival and DFS, the low severe toxicity rates, and the effective benefit on pCR and perioperative metastasis support an intensified treatment regimen for LARC
Disease control, survival, and toxicity outcome after intensified neoadjuvant chemoradiotherapy for locally advanced rectal cancer: a single-institution experience / DE FELICE, Francesca; Musio, Daniela; Magnante, ANNA LISA; Bulzonetti, Nadia; Benevento, Ilaria; Caiazzo, Rossella; Tombolini, Vincenzo. - In: CLINICAL COLORECTAL CANCER. - ISSN 1533-0028. - STAMPA. - 15:2(2016), pp. 17-22. [10.1016/j.clcc.2016.02.006]
Disease control, survival, and toxicity outcome after intensified neoadjuvant chemoradiotherapy for locally advanced rectal cancer: a single-institution experience
DE FELICE, FRANCESCA
Primo
;MAGNANTE, ANNA LISA;BENEVENTO, ILARIA;TOMBOLINI, VincenzoUltimo
2016
Abstract
Development of distant metastasis remains high in locally advanced rectal cancer patients treated with a trimodal approach. We intensified the neoadjuvant treatment regimen by adding oxaliplatin to the standard 5- fluorouracil. Five-year follow-up data were encouraging, with excellent disease control rates and long-term survival. An oxaliplatin-based combination in the neoadjuvant setting could be a valid treatment option. Purpose: To report the long-term follow-up data and determine the toxicity rate concerning patients with locally advanced rectal cancer (LARC) treated with an intensified neoadjuvant treatment regimen. Patients and Methods: Patients with histologically proven stage II to III adenocarcinoma of the rectum were included and treated with a trimodal approach. Intensified neoadjuvant treatment (chemoradiotherapy [CRT]) consisted of radiotherapy (total dose 50.4/54 Gy) and concomitant oxaliplatin (50 mg/m2 /week) and 5-fluorouracil (200 mg/m2 /5 daily continuous infusion). Surgery was planned 7 to 9 weeks after the end of CRT. Adjuvant chemotherapy was recommended in those patients with lymph node metastasis at diagnosis. Results: One hundred patients (median age, 64 years) were eligible. Overall, the 5-year overall survival and disease-free survival (DFS) were 76.4% and 74.5%, respectively. CRT was well tolerated, with only 17% grade 3/4 acute toxicity. Twenty-four patients (24%) had a pathologic complete response (pCR), and only 1 patient had perioperative metastasis. The 5-year DFS were 95.7% and 66.7% for pCR and no-pCR tumor histology, respectively (P ¼ .0275). Conclusion: Although oxaliplatin is not considered to be a standard treatment, the high 5-year rate of overall survival and DFS, the low severe toxicity rates, and the effective benefit on pCR and perioperative metastasis support an intensified treatment regimen for LARCFile | Dimensione | Formato | |
---|---|---|---|
De Felice_Disease_2016.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
259.29 kB
Formato
Adobe PDF
|
259.29 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.